Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 12, 2013, Pages 1834-1841

  Miyaki, Daisuke ^a   Aikata, Hiroshi ^a   Kan, Hiromi ^a   Fujino, Hatsue ^a   Urabe, Ayako ^a   Masaki, Keiichi ^a   Fukuhara, Takayuki ^a   Kobayashi, Tomoki ^a   Naeshiro, Noriaki ^a   Nakahara, Takashi ^a   Kawaoka, Tomokazu ^a   Hiramatsu, Akira ^a   Takahashi, Shoichi ^a   Ishikawa, Masaki ^b   Kakizawa, Hideaki ^b   Awai, Kazuo ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

HAIC; HCC; Prognosis; Response; Sorafenib

Indexed keywords

CISPLATIN; FLUOROURACIL; INTERFERON; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE CONTROL; FEMALE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

HAIC; HCC; PROGNOSIS; RESPONSE; SORAFENIB;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG EVALUATION; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84897664838     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12311     Document Type: Article

References (28)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127: 2893-2917.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006; 24: 2137-2150.
3. Kamada K, Kitamoto M, Aikata H etal. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am. J. Surg. 2002; 184: 284-290.
4. Rossi S, Di Stasi M, Buscarini E etal. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 1996; 167: 759-768.
5. Seong J, Keum KC, Han KH etal. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 43: 393-397.
6. Uka K, Aikata H, Takaki S etal. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 2007; 42: 845-853.
7. Kawaoka T, Aikata H, Takaki S etal. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 2009; 32: 687-694.
8. Hilgard P, Gane E, Blanc J-F etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
9. Cheng A-L, Kang Y-K, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
10. Obi S, Yoshida H, Toune R etal. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997.
11. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
12. Yamasaki T, Kimura T, Kurokawa F etal. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J. Gastroenterol. 2005; 40: 70-78.
13. Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol. Res. 2012; 42: 340-348.
14. Katamura Y, Aikata H, Kimura Y etal. Intraarterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J. Gastroenterol. 2009; 44: 492-502.
15. Ueshima K, Kudo M, Takita M etal. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78: 148-153.
16. Yamashita T, Arai K, Sunagozaka H etal. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281-290.
17. Miyaki D, Aikata H, Honda Y etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child Pugh classification. J. Gastroenterol. Hepatol. 2012; 27: 1850-1857.
18. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol. Res. 2010; 40: 667-685.
19. Eisenhauer EA, Therasse P, Bogaerts J etal. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-247.
20. Uka K, Aikata H, Takaki S etal. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int. 2007; 27: 1209-1216.
21. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (in Japanese), 4th edn. Tokyo: Kanehara, 2000.
22. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol. Res. 2008; 38: 474-483.
23. Kondo M, Morimoto M, Numata K, Nozaki A, Tanaka K. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Jpn J. Clin. Oncol. 2011; 41: 69-75.
24. Shao Y-Y, Huang C-C, Liang PC, Lin Z-Z. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac. J. Clin. Oncol. 2010; 6: 80-88.
25. Kawaoka T, Aikata H, Murakami E etal. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012; 83: 192-200.
26. Llovet JM, Peña CE, Lathia CD etal. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2012; 18: 2290-2300.
27. Niizeki T, Sumie S, Torimura T etal. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J. Gastroenterol. 2012; 47: 686-695.
28. Arao T, Ueshima K, Matsumoto K etal. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57: 1407-1415.